Compare TTWO & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TTWO | IQV |
|---|---|---|
| Founded | 1993 | 1982 |
| Country | United States | United States |
| Employees | 12909 | 93000 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.9B | 43.1B |
| IPO Year | 1999 | 2013 |
| Metric | TTWO | IQV |
|---|---|---|
| Price | $195.05 | $262.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 28 | 20 |
| Target Price | $286.21 | ★ $311.89 |
| AVG Volume (30 Days) | ★ 2.2M | 1.1M |
| Earning Date | 11-09-2026 | 10-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.67 | 4.67 |
| EPS | N/A | ★ 5.24 |
| Revenue | $6,656,400,000.00 | ★ $9,739,000,000.00 |
| Revenue This Year | $28.42 | $7.18 |
| Revenue Next Year | $8.52 | $6.34 |
| P/E Ratio | ★ N/A | $49.24 |
| Revenue Growth | 18.16 | ★ 41.60 |
| 52 Week Low | $183.86 | $154.50 |
| 52 Week High | $265.94 | $284.50 |
| Indicator | TTWO | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 38.60 | 41.74 |
| Support Level | $188.14 | $252.55 |
| Resistance Level | $220.55 | $276.99 |
| Average True Range (ATR) | 5.36 | 10.09 |
| MACD | -0.85 | -1.67 |
| Stochastic Oscillator | 38.14 | 18.75 |
Take-Two is one of the largest global developers and publishers of video games, with labels including Rockstar, 2K, and Zynga. Grand Theft Auto is the firm's biggest franchise, accounting for about 30% of total sales for the past decade. NBA 2K is the industry's dominant basketball video game, with Take-Two releasing a new version annually. Other notable franchises include Red Dead Redemption, Borderlands, and Civilization. Typically, more than three-fourths of the firm's sales are from in-game spending, with the remainder coming from initial game sales. Since acquiring Zynga in 2022, mobile makes up about half of total sales.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.